Accelerate therapeutic antibody discovery with integrated screening platforms, rapid lead generation, and developability-focused candidate selection.
Our antibody discovery workflows are designed to rapidly identify high-affinity therapeutic candidates with optimal developability. From challenging membrane proteins to complex biologic targets, we tailor each discovery strategy to maximize downstream therapeutic success.
Skip 3 weeks of humanization
Our fully human antibody solutions skips the humanization step helping reduce downstream development time and accelerate therapeutic antibody development.
Evaluation of antigen structure, and project objectives by our experts.
Generation of variants using optimized discovery platforms.
Identification of promising binders using advanced screening technologies.
Identification of the best fits according to client’s specific requirements.
Refine promising antibody leads for downstream therapeutic development.
Antibody Discovery for Complex Targets
Proteogenix is the market leader in antibody discovery for complex targets. Whether you’re working with GPCRs, virus-like particles, or MHC peptides, we excel where others struggle. Our expertise spans innovative techniques including NANOBODY® protein service and custom CAR-T cell development, delivering breakthrough solutions that drive your success. Having performed thousands of complex projects, our team of expert can guide you to choose the best method for your project.
Facing challenges with a complex antigen?
Discover our specialized services or contact our team to bring your project to life!
Custom Anti-GPCR Antibodies Custom Virus-Like Particle Antibodies
Custom MHC-peptide complex antibody Find a solution with our experts
Find Your Perfect Match: Choose the right Antibody Discovery Platforms for Your Unique Project
Ideal for rare epitopes and optimal developability
Generate fully-human antibodies with superior drug-like properties from humanized mice. Perfect when targeting rare epitopes or when developability is critical for therapeutic success.
Hybridoma Development Service
Cost-effective solution with natural affinity maturation
An economical approach leveraging in vivo affinity maturation. Best suited for projects requiring reliable antibodies with budget-friendly cost.
Rapid human antibody generation with specialized libraries
The fastest route to fully human antibodies. Our unique cancer and autoimmune libraries maximize your chances of high-affinity binders for disease-related targets. Ideal for toxic or poorly immunogenic antigens.
Tool
Answer a few questions and find the technology that best fits your target, application and timeline.
Bispecific Antibodies
Antibody Drug Conjugates
CAR-T cell antibodies
VHHs
Why ProteoGenix
As an experienced antibody discovery company, ProteoGenix supports programs from antigen strategy through lead selection and optimization — with integrated CRO capabilities across discovery, engineering, production, and characterization.
Deep Scientific Experience
Our long track record in antibody and protein science helps design robust discovery plans aligned with real therapeutic goals.
Reliable Execution
Established workflows and experienced teams improve consistency, reproducibility, and confidence in the discovery process.
Long-Term Development Support
We support clients beyond discovery with antibody engineering, production, and characterization services as programs advance. For biotech and pharma teams, working with a company with long-standing technical depth reduces uncertainty and supports faster progress toward therapeutic leads.
Your dedicated PhD expert supports your project from design to completion, providing strategic recommendations and clear go/no-go checkpoints so you can make data-driven decisions at every stage of antibody discovery.
From challenging antigens to complex therapeutic targets, our team designs customized discovery strategies using the most appropriate platform for your project, helping maximize your chances of identifying high-quality antibody candidates.
Your discoveries remain entirely yours. ProteoGenix operates with no IP restrictions or hidden royalty fees, giving you full ownership of generated antibody sequences and complete freedom for downstream development.
“Throughout the project, we greatly benefited from ProteoGenix’s strong scientific and technical expertise, as well as the dedication and responsiveness of our main contact. Their support was instrumental in overcoming key challenges and in accelerating the translational development of our lead candidate.”
_ Dr. Uwe Haberkorn (Head of Department) at Heidelberg University
*NANOBODY® compound is a registered trademark of Ablynx N.V.
FAQ
Partner with ProteoGenix for antibody discovery services backed by scientific depth, platform capabilities, and more than 25 years of experience in antibody and biologics development. Our integrated CRO model supports biotech and pharma teams from early target analysis through lead optimization and beyond.
